Impact Factor
3.22
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.21
567 total citations
h5-index
29
h5 depth signal
Cited share
65.2%
176 of 270
Total citations
567
Citation footprint
Metric signal
2.22
External metric anchor
Self-citation
8.1%
46 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
459
China
387
United Kingdom
204
Australia
143
France
117
Citing Fields of Research
Hepatitis
1,958
Liver Diseases
156
Liver & Colon Cancer
56
Immunology
47
Substance Abuse
35
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,853
Articles tracked across the journal lifetime
Indexed publication set
270
176 cited publications
Last 12 months
148
12.3 publications/month
Open access share
43.9%
65 OA publications in the last year
Leading citing country
United States
459 citing publications
Leading citing field
Hepatitis
1,958 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1994-
v1n1, 1994-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hepatitis
Broad Categories
Gastroenterology
Hepatitis
MeSH Descriptors
Hepatitis, Viral, Animal
Hepatitis, Viral, Human
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/jvh.70250
Open DOI
Similar Long‐Term Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Initiating Entecavir Versus Tenofovir Alafenamide: A REAL ‐B Study
Data on potential differences in hepatocellular carcinoma (HCC) incidence between entecavir (ETV) and tenofovir alafenamide (TAF) in chronic hepatitis B (CHB) patients are limited. This retrospective multinational study included treatmen...
02
DOI 10.1111/jvh.70247
Open DOI
Timing of Earliest Documented Positive Hepatitis C Laboratory Result Relative to Delivery Among Pregnant Persons With Active Infection in West Virginia, 2022–2023
Direct‐acting antiviral therapy can cure hepatitis C virus (HCV) infection; however, because treatment is not recommended during pregnancy, preconception treatment remains the primary strategy to prevent perinatal HCV exposure. West Virg...
03
DOI 10.1111/jvh.70248
Open DOI
Hepatitis A Virus ( HAV ) Recurrence and De Novo Hepatitis A Acquired at Time of Liver Transplantation: Comparison of Graft HAV Infection and Viral Kinetics
Hepatitis A virus (HAV) infection is an uncommon indication for liver transplantation, and donor‐derived or transfusion‐associated HAV infection is rare. Data describing HAV recurrence or early acquisition following liver transplantation...
04
DOI 10.1111/jvh.70245
Open DOI
Global Underutilization of Antiviral Therapy and Survival Outcomes in Hepatitis B Virus‐Related Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of 78 Studies and 68,243 Patients
Antiviral therapy with nucleos(t)ide analogues is recommended for patients with viremic hepatitis B virus (HBV)‐related cirrhosis regardless of levels of viremia or liver enzymes. However, hepatocellular carcinoma (HCC) is not an antivir...
05
DOI 10.1111/jvh.70244
Open DOI
New Model of Care Achieving Micro‐Elimination of Hepatitis C in the United Kingdom's Largest Prison
Wales aims to achieve the World Health Organisation goal of eliminating hepatitis C (HCV) as a public health threat by 2030, with micro‐elimination in prisons identified as a key target. In January 2022, HMP Berwyn, the largest prison in...
06
DOI 10.1111/jvh.70243
Open DOI
Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in HBeAg ‑Negative Chronic Hepatitis B: Meta‑Analysis of Randomized Trials
Continuous nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) effectively maintains viral suppression but rarely results in functional cure. Finite NA therapy has been proposed to increase rates of HBsAg loss; however, int...
07
DOI 10.1111/jvh.70242
Open DOI
Direct‐Acting Antiviral Therapy in Patients With Hepatocellular Carcinoma Receiving Non‐Curative Treatment: High Sustained Virological Response Rates and Preservation of Liver Functional Reserve
Direct‐acting antivirals (DAAs) cure most chronic hepatitis C virus (HCV) infections, but their impact on liver functional reserve in patients with a history of hepatocellular carcinoma (HCC), particularly after non‐curative HCC treatmen...
08
DOI 10.1111/jvh.70241
Open DOI
Hepatic Steatosis in People With Chronic Hepatitis B in Africa: Prevalence, Correlates, and Clinical Significance
To address data gaps around metabolic liver disease in Africa, within the Hepatitis B in Africa Collaborative Network (HEPSANET), we evaluated participants with chronic hepatitis B virus infection (CHB) for steatotic liver disease (SLD) ...
09
DOI 10.1111/jvh.70240
Open DOI
Becoming Physically Active and Risks of Mortality and Liver‐Related Events in Adults With Chronic Hepatitis B: A Nationwide Cohort Study
Physical activity (PA) confers several health benefits; however, whether increasing PA among physically inactive adults with chronic hepatitis B (CHB) is associated with lower risks of adverse clinical outcomes remains unclear. We used t...
10
DOI 10.1111/jvh.70236
Open DOI
Global, Regional and National Burden of Viral Hepatitis From 1990 to 2021 With Forecasts to 2046: Findings From the Global Burden of Disease Study 2021
Viral hepatitis constitutes a primary cause of liver cirrhosis and carcinoma and ranks as the second leading cause of mortality worldwide due to challenges in early detection and limited preventive measures, thereby posing a significant ...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.